Gland Pharma shares rose 12% to a 52-week high on Tuesday after reporting a 47% rise in June quarter profit. Laurus Labs also maintained strong momentum, reflecting a recovery in select pharma stocks. Meanwhile, the IT sector remains volatile as companies navigate cautious client spending and AI integration challenges.
Gland Pharma experienced a significant market reaction on Tuesday, with its share price surging 12% to reach a new 52-week high. This movement followed the release of the company's financial results for the first quarter of the 2027 fiscal year. The company reported a 47% year-on-year increase in profit after tax, which reached ₹317 crore. Revenue for the period rose by 19.6% to ₹1,800 crore, driven by performance in both the US and European markets.
A central driver for this growth is the company's Contract Development and Manufacturing Organization (CDMO) business. This segment now contributes 50% of total revenue, having expanded by 20% compared to the same period last year. This shift toward contract-based manufacturing has provided a more stable revenue base for the company.
Laurus Labs has also participated in this pharmaceutical sector recovery, with the stock currently trading near all-time highs. The company has seen significant investor interest this year, recording a year-to-date return of approximately 67%. This performance follows a period where the company benefited from the successful integration of new customer contracts and the initial returns from its recent capital expansion projects.
While pharmaceutical companies are showing signs of growth, the broader information technology sector is facing a different environment. Although artificial intelligence presents opportunities for future demand, the sector is currently navigating short-term challenges. This includes cautious spending by global clients and the operational pressure to re-skill workforces to keep up with rapid technological changes.
Investors tracking these companies should be aware of the varying risks. For Laurus Labs, analysts have highlighted concerns regarding higher valuations following the recent stock rally, alongside the impact that significant capital spending may have on return ratios. In the IT sector, the key monitorable remains whether companies can successfully transition their business models to include AI services without facing margin pressure from increased investment costs.
For Gland Pharma, the focus now shifts to whether the company can maintain the current growth trajectory in its CDMO segment. Shareholders will likely look for updates on execution, particularly regarding the profitability of new product launches and the management of its manufacturing capacity in the coming quarters.